ZA200402090B - Piperazine derivatives with CCR1 receptor antagonist activity. - Google Patents
Piperazine derivatives with CCR1 receptor antagonist activity. Download PDFInfo
- Publication number
- ZA200402090B ZA200402090B ZA200402090A ZA200402090A ZA200402090B ZA 200402090 B ZA200402090 B ZA 200402090B ZA 200402090 A ZA200402090 A ZA 200402090A ZA 200402090 A ZA200402090 A ZA 200402090A ZA 200402090 B ZA200402090 B ZA 200402090B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- oxo
- heteroaryl
- piperazin
- ethoxy
- Prior art date
Links
- 102000004500 CCR1 Receptors Human genes 0.000 title claims description 6
- 108010017319 CCR1 Receptors Proteins 0.000 title claims description 6
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 4
- 230000000694 effects Effects 0.000 title description 3
- 150000004885 piperazines Chemical class 0.000 title description 3
- 239000002464 receptor antagonist Substances 0.000 title description 3
- 229940044551 receptor antagonist Drugs 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 557
- 150000001875 compounds Chemical class 0.000 claims description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 32
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 15
- 125000001475 halogen functional group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229910002514 Co–Co Inorganic materials 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- CZQJMJLEVCMSBJ-JKSUJKDBSA-N 1-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-2-(2h-tetrazol-5-yl)ethanone Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CC=2NN=NN=2)N1CC1=CC=C(F)C=C1 CZQJMJLEVCMSBJ-JKSUJKDBSA-N 0.000 claims description 2
- GFJLRNLVDYYLPZ-WAPIFTKLSA-N 1-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methoxy]-2-oxopropane-1-sulfonamide Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)COC(C(C)=O)S(N)(=O)=O)N1CC1=CC=C(F)C=C1 GFJLRNLVDYYLPZ-WAPIFTKLSA-N 0.000 claims description 2
- KWMJBYQURSKNBZ-JKSUJKDBSA-N 2-[5-chloro-2-[2-[(2r,5s)-4-[(4-chlorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CC(O)=O)N1CC1=CC=C(Cl)C=C1 KWMJBYQURSKNBZ-JKSUJKDBSA-N 0.000 claims description 2
- CJJUSUIRXBUUFT-JKSUJKDBSA-N 2-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]sulfamoyl]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)NS(=O)(=O)CC(O)=O)N1CC1=CC=C(F)C=C1 CJJUSUIRXBUUFT-JKSUJKDBSA-N 0.000 claims description 2
- 206010027654 Allergic conditions Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- BFASLUYYEWJARU-HXUWFJFHSA-N [5-bromo-2-[2-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]phenyl]methanesulfonamide Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Br)=CC=2)CS(N)(=O)=O)CC)N1CC1=CC=C(F)C=C1 BFASLUYYEWJARU-HXUWFJFHSA-N 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000002689 xenotransplantation Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 2
- AYDTUIKSQLGKQV-DLBZAZTESA-N 2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-n-methylsulfonylacetamide Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CC(=O)NS(C)(=O)=O)N1CC1=CC=C(F)C=C1 AYDTUIKSQLGKQV-DLBZAZTESA-N 0.000 claims 1
- ZYRLSHDWENZTDU-JKSUJKDBSA-N 2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]pyridin-3-yl]-n-methylsulfonylacetamide Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CN=2)CC(=O)NS(C)(=O)=O)N1CC1=CC=C(F)C=C1 ZYRLSHDWENZTDU-JKSUJKDBSA-N 0.000 claims 1
- KXRQGAVRWOLUCJ-LSDHHAIUSA-N 2-[[5-chloro-2-[[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethyl]amino]pyridine-3-carbonyl]amino]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)CNC=2C(=CC(Cl)=CN=2)C(=O)NCC(O)=O)N1CC1=CC=C(F)C=C1 KXRQGAVRWOLUCJ-LSDHHAIUSA-N 0.000 claims 1
- QOKPWFMMDLUQSW-JKSUJKDBSA-N 2-amino-5-[2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-2-oxoethyl]-1h-pyrimidine-4,6-dione Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CC2C(NC(=N)NC2=O)=O)N1CC1=CC=C(F)C=C1 QOKPWFMMDLUQSW-JKSUJKDBSA-N 0.000 claims 1
- SRKGGHINULUDFS-RBUKOAKNSA-N 3-[2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]-5-methylphenyl]propanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(C)=CC=2)CCC(O)=O)N1CC1=CC=C(F)C=C1 SRKGGHINULUDFS-RBUKOAKNSA-N 0.000 claims 1
- IGCJNRKTJVOHFQ-MRXNPFEDSA-N 4-[5-chloro-2-[2-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]-4-oxobutanoic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CCC(O)=O)C)N1CC1=CC=C(F)C=C1 IGCJNRKTJVOHFQ-MRXNPFEDSA-N 0.000 claims 1
- TUQWRSJSWFVFSD-DLBZAZTESA-N 4-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-4-oxobutanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CCC(O)=O)N1CC1=CC=C(F)C=C1 TUQWRSJSWFVFSD-DLBZAZTESA-N 0.000 claims 1
- FHBKTQJLMAVTCL-JKSUJKDBSA-N 4-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]pyridin-3-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CN=2)NC(=O)CCC(O)=O)N1CC1=CC=C(F)C=C1 FHBKTQJLMAVTCL-JKSUJKDBSA-N 0.000 claims 1
- SMXJQQCPHSYTHW-DLBZAZTESA-N 4-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]pyridin-3-yl]amino]butanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CN=2)NCCCC(O)=O)N1CC1=CC=C(F)C=C1 SMXJQQCPHSYTHW-DLBZAZTESA-N 0.000 claims 1
- 229940006015 4-hydroxybutyric acid Drugs 0.000 claims 1
- LFECXYJPKUQIFL-JKSUJKDBSA-N 5-[2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-2-oxoethyl]-1,3-diazinane-2,4,6-trione Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CC2C(NC(=O)NC2=O)=O)N1CC1=CC=C(F)C=C1 LFECXYJPKUQIFL-JKSUJKDBSA-N 0.000 claims 1
- HUZAGFHEBHQDHO-ZWKOTPCHSA-N 5-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-5-oxopentanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CCCC(O)=O)N1CC1=CC=C(F)C=C1 HUZAGFHEBHQDHO-ZWKOTPCHSA-N 0.000 claims 1
- MJXUGOAYBNWVGU-NCHORFDRSA-N 6-[2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-2-oxoethyl]-1,4-diazepane-2,5,7-trione Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C(=O)CC2C(NC(=O)CNC2=O)=O)N1CC1=CC=C(F)C=C1 MJXUGOAYBNWVGU-NCHORFDRSA-N 0.000 claims 1
- AQGPBJMKJFSKBQ-RBUKOAKNSA-N 6-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenoxy]methyl]pyridine-3-carboxylic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)OCC=2N=CC(=CC=2)C(O)=O)N1CC1=CC=C(F)C=C1 AQGPBJMKJFSKBQ-RBUKOAKNSA-N 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XKLJKRUBNXGTHT-JOCHJYFZSA-N n-[[5-chloro-2-[2-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]phenyl]methylsulfonyl]acetamide Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CS(=O)(=O)NC(C)=O)CC)N1CC1=CC=C(F)C=C1 XKLJKRUBNXGTHT-JOCHJYFZSA-N 0.000 claims 1
- PVHIGSGWDVVQGD-DLBZAZTESA-N n-[[5-chloro-2-[2-[(2r,5s)-4-[(4-chlorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methylsulfonyl]acetamide Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CS(=O)(=O)NC(C)=O)N1CC1=CC=C(Cl)C=C1 PVHIGSGWDVVQGD-DLBZAZTESA-N 0.000 claims 1
- 238000002402 nanowire electron scattering Methods 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 4
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 2
- LUWJLQBRPIPHRL-RCCFBDPRSA-N (2r)-2-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methoxy]propanoic acid Chemical compound OC(=O)[C@@H](C)OCC1=CC(Cl)=CC=C1OCC(=O)N1[C@H](C)CN(CC=2C=CC(F)=CC=2)[C@@H](C)C1 LUWJLQBRPIPHRL-RCCFBDPRSA-N 0.000 description 1
- DRJVRDDBKOFPFT-CSODHUTKSA-N (2r)-2-amino-4-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenoxy]butanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)OCC[C@@H](N)C(O)=O)N1CC1=CC=C(F)C=C1 DRJVRDDBKOFPFT-CSODHUTKSA-N 0.000 description 1
- LUWJLQBRPIPHRL-KSZLIROESA-N (2s)-2-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OCC1=CC(Cl)=CC=C1OCC(=O)N1[C@H](C)CN(CC=2C=CC(F)=CC=2)[C@@H](C)C1 LUWJLQBRPIPHRL-KSZLIROESA-N 0.000 description 1
- ABYZSYDGJGVCHS-ZETCQYMHSA-N (2s)-2-acetamido-n-(4-nitrophenyl)propanamide Chemical compound CC(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ABYZSYDGJGVCHS-ZETCQYMHSA-N 0.000 description 1
- DRJVRDDBKOFPFT-FVJLSDCUSA-N (2s)-2-amino-4-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenoxy]butanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)OCC[C@H](N)C(O)=O)N1CC1=CC=C(F)C=C1 DRJVRDDBKOFPFT-FVJLSDCUSA-N 0.000 description 1
- -1 (6-Bromo-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo- ethoxy}-phenoxy)-difluoro-acetic acid Chemical compound 0.000 description 1
- ZENLGDUALOBRJK-FCHUYYIVSA-N 1-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methyl]-3-(2-methylphenyl)sulfonylurea Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CNC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)N1CC1=CC=C(F)C=C1 ZENLGDUALOBRJK-FCHUYYIVSA-N 0.000 description 1
- XDGCUAKXSXQEMI-DLBZAZTESA-N 1-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methyl]-3-methylsulfonylurea Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CNC(=O)NS(C)(=O)=O)N1CC1=CC=C(F)C=C1 XDGCUAKXSXQEMI-DLBZAZTESA-N 0.000 description 1
- IIRCOMNXRWJBSX-GOSISDBHSA-N 2-[2-[2-[(2r)-2-(2-amino-2-oxoethyl)-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]-5-chlorophenoxy]acetic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)OCC(O)=O)CC(=O)N)N1CC1=CC=C(F)C=C1 IIRCOMNXRWJBSX-GOSISDBHSA-N 0.000 description 1
- SWFGITYSDQMEEO-RBUKOAKNSA-N 2-[2-[3-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-3-oxopropyl]-5-methylphenoxy]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)CCC=2C(=CC(C)=CC=2)OCC(O)=O)N1CC1=CC=C(F)C=C1 SWFGITYSDQMEEO-RBUKOAKNSA-N 0.000 description 1
- DAMUKCUMVKETRF-CQSZACIVSA-N 2-[4-chloro-2-(2h-tetrazol-5-yloxy)phenoxy]-1-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]ethanone Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)OC2=NNN=N2)C)N1CC1=CC=C(F)C=C1 DAMUKCUMVKETRF-CQSZACIVSA-N 0.000 description 1
- FLRARSXQMVYTHN-DLBZAZTESA-N 2-[4-chloro-2-(5-hydroxyfuran-2-yl)phenoxy]-1-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]ethanone Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C=2OC(O)=CC=2)N1CC1=CC=C(F)C=C1 FLRARSXQMVYTHN-DLBZAZTESA-N 0.000 description 1
- KTESWLABQJPLQP-MRXNPFEDSA-N 2-[5-bromo-2-[2-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenoxy]-2-methylpropanoic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Br)=CC=2)OC(C)(C)C(O)=O)C)N1CC1=CC=C(F)C=C1 KTESWLABQJPLQP-MRXNPFEDSA-N 0.000 description 1
- UHBQPDPLLOCUFW-OAHLLOKOSA-N 2-[5-bromo-2-[2-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Br)=CC=2)CC(O)=O)C)N1CC1=CC=C(F)C=C1 UHBQPDPLLOCUFW-OAHLLOKOSA-N 0.000 description 1
- YDHMAZQMAIDXGR-JKSUJKDBSA-N 2-[5-bromo-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenoxy]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Br)=CC=2)OCC(O)=O)N1CC1=CC=C(F)C=C1 YDHMAZQMAIDXGR-JKSUJKDBSA-N 0.000 description 1
- XSNMOJCERAMFBQ-JKSUJKDBSA-N 2-[5-bromo-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Br)=CC=2)CC(O)=O)N1CC1=CC=C(F)C=C1 XSNMOJCERAMFBQ-JKSUJKDBSA-N 0.000 description 1
- KPKOCXTWMVIQNU-LJQANCHMSA-N 2-[5-chloro-2-[2-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]phenoxy]acetic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)OCC(O)=O)CC)N1CC1=CC=C(F)C=C1 KPKOCXTWMVIQNU-LJQANCHMSA-N 0.000 description 1
- XCQQIUNCNMPFLL-HXUWFJFHSA-N 2-[5-chloro-2-[2-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]phenyl]acetic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CC(O)=O)CC)N1CC1=CC=C(F)C=C1 XCQQIUNCNMPFLL-HXUWFJFHSA-N 0.000 description 1
- APXSDQRQJDNPFK-OAHLLOKOSA-N 2-[5-chloro-2-[2-[(2r)-4-[(4-chlorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CC(O)=O)C)N1CC1=CC=C(Cl)C=C1 APXSDQRQJDNPFK-OAHLLOKOSA-N 0.000 description 1
- BRGYBFDPPWRXOR-ZWKOTPCHSA-N 2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenoxy]-6-methylpyrimidine-4-carboxylic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)OC=2N=C(C=C(C)N=2)C(O)=O)N1CC1=CC=C(F)C=C1 BRGYBFDPPWRXOR-ZWKOTPCHSA-N 0.000 description 1
- SNYODKVYELSBHG-JKSUJKDBSA-N 2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenoxy]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)OCC(O)=O)N1CC1=CC=C(F)C=C1 SNYODKVYELSBHG-JKSUJKDBSA-N 0.000 description 1
- IAMNFIUUZVYKLE-VQTJNVASSA-N 2-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]-n-(2-chlorophenyl)sulfonylacetamide Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)N1CC1=CC=C(F)C=C1 IAMNFIUUZVYKLE-VQTJNVASSA-N 0.000 description 1
- JZSYWQGEEWEFGY-DLBZAZTESA-N 2-[5-chloro-2-[3-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-3-oxopropyl]phenoxy]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)CCC=2C(=CC(Cl)=CC=2)OCC(O)=O)N1CC1=CC=C(F)C=C1 JZSYWQGEEWEFGY-DLBZAZTESA-N 0.000 description 1
- JGQSTRLXVJERQN-DLBZAZTESA-N 2-[[5-bromo-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methylideneamino]oxyacetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Br)=CC=2)C=NOCC(O)=O)N1CC1=CC=C(F)C=C1 JGQSTRLXVJERQN-DLBZAZTESA-N 0.000 description 1
- OXOCBSLPCPTKBP-OAHLLOKOSA-N 2-[[5-chloro-2-[2-[(2r)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]methylsulfonylamino]-2-oxoacetic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CS(=O)(=O)NC(=O)C(O)=O)C)N1CC1=CC=C(F)C=C1 OXOCBSLPCPTKBP-OAHLLOKOSA-N 0.000 description 1
- QWJJKPWBZUHENV-LSDHHAIUSA-N 2-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]pyridin-3-yl]amino]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CN=2)NCC(O)=O)N1CC1=CC=C(F)C=C1 QWJJKPWBZUHENV-LSDHHAIUSA-N 0.000 description 1
- RKFCTIKREBQPJG-LSDHHAIUSA-N 2-[[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]pyridine-3-carbonyl]amino]acetic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CN=2)C(=O)NCC(O)=O)N1CC1=CC=C(F)C=C1 RKFCTIKREBQPJG-LSDHHAIUSA-N 0.000 description 1
- VVOPROFCWVHWIX-PTHSTZKBSA-N 2-amino-3-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)CC(N)C(O)=O)N1CC1=CC=C(F)C=C1 VVOPROFCWVHWIX-PTHSTZKBSA-N 0.000 description 1
- RKOSUFRDDZSJGO-JOCHJYFZSA-N 3-[2-[2-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]-5-methylphenyl]propanoic acid Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(C)=CC=2)CCC(O)=O)CC)N1CC1=CC=C(F)C=C1 RKOSUFRDDZSJGO-JOCHJYFZSA-N 0.000 description 1
- NTSOZYGLZANGMS-RBUKOAKNSA-N 3-[2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]-5-methylphenyl]prop-2-enoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(C)=CC=2)C=CC(O)=O)N1CC1=CC=C(F)C=C1 NTSOZYGLZANGMS-RBUKOAKNSA-N 0.000 description 1
- KWYQAPYSFVBNPW-DLBZAZTESA-N 3-[5-bromo-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]prop-2-enoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Br)=CC=2)C=CC(O)=O)N1CC1=CC=C(F)C=C1 KWYQAPYSFVBNPW-DLBZAZTESA-N 0.000 description 1
- UGHANAHUOZSATC-DLBZAZTESA-N 3-[5-bromo-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Br)=CC=2)CCC(O)=O)N1CC1=CC=C(F)C=C1 UGHANAHUOZSATC-DLBZAZTESA-N 0.000 description 1
- ORZLFJQOUNXMRD-DLBZAZTESA-N 3-[5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]prop-2-enoic acid Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)C=CC(O)=O)N1CC1=CC=C(F)C=C1 ORZLFJQOUNXMRD-DLBZAZTESA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000728693 Homo sapiens 28S ribosomal protein S11, mitochondrial Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027236 Meningitis fungal Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- IMGKQDGULOZFQT-JKSUJKDBSA-N [5-bromo-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methanesulfonamide Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Br)=CC=2)CS(N)(=O)=O)N1CC1=CC=C(F)C=C1 IMGKQDGULOZFQT-JKSUJKDBSA-N 0.000 description 1
- DROSBWNJXSLBQX-HXUWFJFHSA-N [5-chloro-2-[2-[(2r)-2-ethyl-4-[(4-fluorophenyl)methyl]piperazin-1-yl]-2-oxoethoxy]phenyl]methanesulfonamide Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CS(N)(=O)=O)CC)N1CC1=CC=C(F)C=C1 DROSBWNJXSLBQX-HXUWFJFHSA-N 0.000 description 1
- YTIYHDOAOIQQIA-CQSZACIVSA-N [5-chloro-2-[2-[(2r)-4-[(3,4-difluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]methanesulfonamide Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CS(N)(=O)=O)C)N1CC1=CC=C(F)C(F)=C1 YTIYHDOAOIQQIA-CQSZACIVSA-N 0.000 description 1
- RPAKOKNIUPPCHY-OAHLLOKOSA-N [5-chloro-2-[2-[(2r)-4-[(4-chlorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]methanesulfonamide Chemical compound C([C@H](N(CC1)C(=O)COC=2C(=CC(Cl)=CC=2)CS(N)(=O)=O)C)N1CC1=CC=C(Cl)C=C1 RPAKOKNIUPPCHY-OAHLLOKOSA-N 0.000 description 1
- IASZITNAXYOQNN-FCHUYYIVSA-N [5-chloro-2-[2-[(2r,5s)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]methyl n-(2-methylphenyl)sulfonylcarbamate Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)COC=2C(=CC(Cl)=CC=2)COC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)N1CC1=CC=C(F)C=C1 IASZITNAXYOQNN-FCHUYYIVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 201000010056 fungal meningitis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33860101P | 2001-10-22 | 2001-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200402090B true ZA200402090B (en) | 2005-05-23 |
Family
ID=23325393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200402090A ZA200402090B (en) | 2001-10-22 | 2004-03-16 | Piperazine derivatives with CCR1 receptor antagonist activity. |
Country Status (35)
Country | Link |
---|---|
US (1) | US7098212B2 (cs) |
EP (1) | EP1438298B1 (cs) |
JP (1) | JP2005507923A (cs) |
KR (1) | KR20040047941A (cs) |
CN (1) | CN1575283A (cs) |
AP (1) | AP2004003008A0 (cs) |
AR (1) | AR037742A1 (cs) |
AT (1) | ATE456559T1 (cs) |
BG (1) | BG108674A (cs) |
BR (1) | BR0213452A (cs) |
CA (1) | CA2463272C (cs) |
CZ (1) | CZ2004519A3 (cs) |
DE (1) | DE60235249D1 (cs) |
DK (1) | DK1438298T3 (cs) |
EA (1) | EA006243B1 (cs) |
EC (1) | ECSP045073A (cs) |
EE (1) | EE200400088A (cs) |
ES (1) | ES2337241T3 (cs) |
HN (1) | HN2002000300A (cs) |
HR (1) | HRP20040289A2 (cs) |
HU (1) | HUP0401735A3 (cs) |
IL (1) | IL160974A0 (cs) |
IS (1) | IS7180A (cs) |
MA (1) | MA27142A1 (cs) |
MX (1) | MXPA04002423A (cs) |
NO (1) | NO20041631L (cs) |
OA (1) | OA12670A (cs) |
PA (1) | PA8556901A1 (cs) |
PE (1) | PE20030568A1 (cs) |
PL (1) | PL370548A1 (cs) |
SK (1) | SK1852004A3 (cs) |
TN (1) | TNSN04072A1 (cs) |
UY (1) | UY27503A1 (cs) |
WO (1) | WO2003035627A1 (cs) |
ZA (1) | ZA200402090B (cs) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
US20040092529A1 (en) * | 2002-10-30 | 2004-05-13 | Pfizer Inc | Methods of using piperazine derivatives |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
CA2573223C (en) | 2004-08-06 | 2013-05-21 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compound |
PL1906965T3 (pl) * | 2005-06-22 | 2015-10-30 | Chemocentryx Inc | Związki azaindazolowe i sposoby zastosowania |
US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
DK1957073T3 (da) | 2005-12-05 | 2014-05-12 | Otsuka Pharma Co Ltd | Lægemiddel |
DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
EP2174667B1 (en) * | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
AU2010333829A1 (en) | 2009-12-23 | 2012-07-12 | Ironwood Pharmaceuticals, Inc. | CRTH2 modulators |
WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
US20130216552A1 (en) | 2010-07-12 | 2013-08-22 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
FR2976943B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
CN103012318B (zh) * | 2012-11-25 | 2014-12-10 | 大理学院 | 氟苄基取代哌嗪类化合物及其制备和医药用途 |
CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
GB201918692D0 (en) | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
CN113754616B (zh) * | 2021-09-27 | 2023-07-18 | 北京工商大学 | 一种反式-3-苯硫基-γ-内酯的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (cs) * | 1962-12-19 | |||
US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
IT1156990B (it) * | 1978-04-27 | 1987-02-04 | Geymonat Sud Spa | Procedimento per la preparazione del cloridrato di p clorofenossiacetil piperonilpierazina |
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
IT1255704B (it) * | 1992-09-30 | 1995-11-10 | Boehringer Mannheim Italia | Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree |
IL110040A (en) | 1993-06-29 | 2000-07-16 | Nissan Chemical Ind Ltd | Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them |
RO115159B1 (ro) * | 1995-01-11 | 1999-11-30 | Samjin Pharmaceutical Co., Ltd | Derivaţi de piperazină şi compoziţii farmaceutice care îi conţin |
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
PL358618A1 (en) * | 2000-03-31 | 2004-08-09 | Pfizer Products Inc. | Novel piperazine derivatives |
JP2004511558A (ja) | 2000-10-19 | 2004-04-15 | ファイザー・プロダクツ・インク | 架橋ピペラジン誘導体 |
UY27003A1 (es) | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
-
2002
- 2002-09-26 HU HU0401735A patent/HUP0401735A3/hu unknown
- 2002-09-26 EE EEP200400088A patent/EE200400088A/xx unknown
- 2002-09-26 AP APAP/P/2004/003008A patent/AP2004003008A0/en unknown
- 2002-09-26 MX MXPA04002423A patent/MXPA04002423A/es active IP Right Grant
- 2002-09-26 EP EP02772651A patent/EP1438298B1/en not_active Expired - Lifetime
- 2002-09-26 EA EA200400466A patent/EA006243B1/ru not_active IP Right Cessation
- 2002-09-26 IL IL16097402A patent/IL160974A0/xx unknown
- 2002-09-26 BR BR0213452-7A patent/BR0213452A/pt not_active IP Right Cessation
- 2002-09-26 DK DK02772651.2T patent/DK1438298T3/da active
- 2002-09-26 CN CNA028208889A patent/CN1575283A/zh active Pending
- 2002-09-26 CA CA002463272A patent/CA2463272C/en not_active Expired - Fee Related
- 2002-09-26 DE DE60235249T patent/DE60235249D1/de not_active Expired - Lifetime
- 2002-09-26 OA OA1200400110A patent/OA12670A/en unknown
- 2002-09-26 JP JP2003538143A patent/JP2005507923A/ja not_active Ceased
- 2002-09-26 WO PCT/IB2002/003989 patent/WO2003035627A1/en not_active Application Discontinuation
- 2002-09-26 SK SK185-2004A patent/SK1852004A3/sk unknown
- 2002-09-26 PL PL02370548A patent/PL370548A1/xx not_active Application Discontinuation
- 2002-09-26 AT AT02772651T patent/ATE456559T1/de not_active IP Right Cessation
- 2002-09-26 ES ES02772651T patent/ES2337241T3/es not_active Expired - Lifetime
- 2002-09-26 KR KR10-2004-7005885A patent/KR20040047941A/ko not_active Application Discontinuation
- 2002-09-26 CZ CZ2004519A patent/CZ2004519A3/cs unknown
- 2002-10-18 US US10/273,658 patent/US7098212B2/en not_active Expired - Fee Related
- 2002-10-18 PE PE2002001033A patent/PE20030568A1/es not_active Application Discontinuation
- 2002-10-18 UY UY27503A patent/UY27503A1/es not_active Application Discontinuation
- 2002-10-18 PA PA20028556901A patent/PA8556901A1/es unknown
- 2002-10-18 HN HN2002000300A patent/HN2002000300A/es unknown
- 2002-10-21 AR ARP020103961A patent/AR037742A1/es unknown
-
2004
- 2004-03-11 IS IS7180A patent/IS7180A/is unknown
- 2004-03-16 ZA ZA200402090A patent/ZA200402090B/en unknown
- 2004-03-23 HR HR20040289A patent/HRP20040289A2/hr not_active Application Discontinuation
- 2004-04-08 BG BG108674A patent/BG108674A/xx unknown
- 2004-04-15 MA MA27631A patent/MA27142A1/fr unknown
- 2004-04-21 TN TNP2004000072A patent/TNSN04072A1/fr unknown
- 2004-04-21 NO NO20041631A patent/NO20041631L/no unknown
- 2004-04-22 EC EC2004005073A patent/ECSP045073A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200402090B (en) | Piperazine derivatives with CCR1 receptor antagonist activity. | |
US6090807A (en) | Use of heterocyclic compounds | |
DE60214392T2 (de) | 1,4-Disubstituierte Benzo-kondensierte Cycloalkyl-Harnstoffverbindungen | |
US7642277B2 (en) | Non-nucleoside reverse transcriptase inhibitors | |
US6855706B2 (en) | Phenylalanine derivatives | |
US20040092529A1 (en) | Methods of using piperazine derivatives | |
US7494989B2 (en) | Pyridine compounds useful as N-type calcium channel antagonists | |
US8809343B2 (en) | Pyrimidine derivative, preparation method and use thereof | |
JP2004530690A (ja) | 抗炎症性薬剤として有用なジアリールウレア誘導体 | |
JP2005537313A5 (cs) | ||
WO2001053263A1 (en) | Corticotropin releasing factor antagonists | |
DE60014369T2 (de) | Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern | |
CZ20033455A3 (en) | Novel sulfonic acid derivatives | |
CH707498B1 (de) | Heterocyclische Dihydro-Fünfring-Ketonderivate als DHODH-Inhibitor und ihre Verwendung. | |
US6987114B1 (en) | Antiviral pyrimidinedione derivatives and process for the preparation thereof | |
US4997835A (en) | Substituted 2-acylpyridine-α-(N)-hetarlyhydrazones and medicaments containing the same | |
JP2007532654A5 (cs) | ||
CN109053591A (zh) | 含联苯结构的二芳基嘧啶类衍生物及其制备方法和用途 | |
US20220411419A1 (en) | Small molecule modulators of mhc-i | |
EP0740649A1 (de) | Nitroxy-gruppen enthaltende benzylaminderivate und ihre verwendung zur behandlung von cardiovasculären erkrankungen sowie erhöhtem augeninnendruck | |
RU2590163C2 (ru) | Производные 6-метил-4-фенил-5-(фенил или циклоалкил)-карбамоил-1,2,3,4-тетрагидропиримидин-2-она в качестве противотуберкулезных средств | |
DD258604A5 (de) | Verfahren zur herstellung von neuen ungesaettigten verbindungen | |
KR101241370B1 (ko) | 신규한 티오우레아 또는 우레아 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
AU2002337408A1 (en) | Piperazine derivatives with CCR1 receptor antagonist activity | |
Chemiefarma | New Patents v halogen atom, or a lower alkyl, lower alkoxy radical, or R3 and R4 are bonded to adjacent carbon atoms and together denote a methylenedioxy or ethylenedioxy radical, Z is an |